Evercore ISI ranked #1 in Financials in Institutional Investor’s 2023 poll. We cover Banks (Large-Cap and Regional), Asset Managers, Consumer Finance and Insurance (Life and P&C). The team is renowned for deep relationships with management teams, timely deep dives into complex areas impacting stocks, balance sheet-focused analytical work, and ...

1 day ago · Evercore ISI analyst David Palmer maintained a Buy rating on Restaurant Brands International (QSR – Research Report) yesterday and set a price target of $86.00. The company’s shares closed ...

NEW YORK, October 29, 2024 -- (BUSINESS WIRE)--Evercore ISI was ranked No. 1 among all firms for top-ranked analysts on a weighted basis in Extel’s (previously Institutional Investor) All-America...

Evercore ISI’s dedicated team of sales and trading professionals serves more than 1,300 institutional investors globally, representing the largest asset managers and fund complexes in the world. With a combined force of nearly 70 sales and trading professionals, our team rivals the size and experience of any sell-side firm.

4 days ago · Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming financial results on Feb. 26. Leverage the power of TipRanks' Smart ...

In August 2014, Evercore announced the acquisition of International Strategy & Investment ("ISI") Group for $440 million. [14][15] The deal was closed the following October to create Evercore ISI Institutional Equities, offering Macro and Fundamental Research, Sales, and Trading execution.

Feb 4, 2025 · Investing.com -- Evercore ISI lifted Juniper Networks (NYSE:JNPR) stock to Outperform from In-Line on Tuesday while maintaining a $40 price target. Juniper shares rose nearly 2% after the market open.

Feb 7, 2025 · Evercore ISI is committed to delivering the highest-quality corporate access and conferences for value-added outcomes benefiting both investors and corporates.

1 day ago · Evercore ISI analyst Kirk Materne maintained a Hold rating on Tyler Technologies (TYL – Research Report) yesterday and set a price target of $620.00. The company’s shares closed yesterday at ...

The new price target of $99 takes into account the potential of CRISPR Therapeutics' in vivo programs, CTX320 and CTX310. Evercore ISI has assigned a probability of success (POS) of 10% and 5% to ...